MedTrace Logo

Role of Axumin PET Scan in Germ Cell Tumor

NCT03426865 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-08-11

No results posted yet for this study

Summary

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

Conditions

  • Testis Cancer
  • Germ Cell Tumor
  • Testicular Cancer
  • Germ Cell Tumor of Testis
  • Germ Cell Tumor, Testicular, Childhood
  • Testicular Neoplasms
  • Testicular Germ Cell Tumor
  • Testicular Yolk Sac Tumor
  • Testicular Choriocarcinoma
  • Testicular Diseases
  • Germ Cell Cancer Metastatic
  • Germ Cell Neoplasm of Retroperitoneum
  • Germ Cell Cancer, Nos

Interventions

DRUG

Axumin PET scan

PET scan prior to RPLND

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Yair Lotan, MD · University of Texas Southwestern Medical Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2023-06-01
Completion
2023-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426865 on ClinicalTrials.gov